Drugs / AMDX-2011P
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06514001 | Mar 2025 → Sep 2026 overdue | Alzheimer disease | Amydis Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05709314 | Jul 2024 → Dec 2026 expected | cerebral amyloid angiopathy | Amydis Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06223048 | Dec 2023 → Nov 2024 overdue | open-angle glaucoma | Amydis Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMDX-2011P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06514001 ↗ |
| Modality | Diagnostic / imaging agent | “as a Retinal Tracer in Participants With Alzheimer's Disease” NCT06514001 ↗ |
| Route | Intravenous | “administered through a single IV bolus injection” NCT05709314 ↗ |